AF
CASI icon

Advisornet Financial’s CASI Pharmaceuticals CASI Stock Holding History

Advisornet Financial’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26
Closed -$56 – 2253
2025
Q1 		$56 Buy
+26
New +$64 ﹤0.01% 2131

Other funds holding CASI

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Advisornet Financial's CASI Position: Q2 2025 in Review

Advisornet Financial sold out of CASI Pharmaceuticals (CASI) in Q2 2025, closing a stake of 26 shares — an estimated $56 sold.

Advisornet Financial first reported a position in CASI in Q1 2025 and held it in 1 quarter. The position peaked at $56 in Q1 2025. 24 funds tracked by Wall St. Rank hold CASI as of Q2 2025.

  • Advisornet Financial reported no remaining CASI Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Advisornet Financial sold 26 CASI Pharmaceuticals shares in Q2 2025, an estimated $56.
  • Advisornet Financial first reported a position in CASI Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Advisornet Financial's CASI Pharmaceuticals position peaked at $56 in Q1 2025.
  • 24 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2025.

Based on Advisornet Financial's 13F filing for Q2 2025, filed 14 Jul 2025.